This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Ovarian Cancer
  • /
  • Final overall survival (OS) results from SOLO2/ENG...
Journal

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation

Read time: 1 mins
Published:1st May 2020
Author: Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM et al.
Availability: Pay for access, or by subscription
Ref.:ournal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 6002-6002.
DOI:10.1200/JCO.2020.38.15_suppl.6002
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest